



Urgent[®] PC

OUTPATIENT TREATMENT FOR
OVERACTIVE BLADDER SYMPTOMS



Innovation for Health

URGENT® PC NEUROMODULATION SYSTEM

Since 2003, Urgent PC has set the standard for Percutaneous Tibial Nerve Stimulation (PTNS) performance, both in clinical studies and in clinical practice.

PROVEN OPTION: FOR MOST PATIENTS WITH ASSOCIATED SYMPTOMS OF OVERACTIVE BLADDER (OAB)

Urgent PC is low-risk with few contraindications and no severe adverse events. Urgent PC is a good option for most patients suffering from urinary urgency, urinary frequency, and urge incontinence.

- Outpatient neuromodulation
- Effective in both men and women, regardless of age¹
- Low-risk with few contraindications and no severe adverse events
- May be combined with behavioral and drug therapies

URGENT PC CANDIDATES INCLUDE THOSE:

- Too old and/or frail for other therapies
- Suffering intolerable side-effects from other therapies
- Experiencing insufficient response to drugs
- Already receiving BOTOX® injections
- Unwilling to perform self-catheterization
- Needing future MRIs
- Who want a non-drug, non-surgical option




The tibial nerve is easily accessed in the lower leg. Stimulation travels from the point of entry near the ankle, up the tibial nerve and to the sacral plexus.




PATIENT PREFERRED: REFRACTORY TREATMENT FOR ASSOCIATED SYMPTOMS OF OAB

- First choice among next line therapies for patients who are refractory to conservative and drug therapies²
- 98% of patients were willing to try PTNS²



PROVEN EFFECTIVE: 50 STUDIES DEMONSTRATE PRODUCT PERFORMANCE

URGENT® PC SUPERIOR TO SHAM (P<0.001)
Patients Reporting Improvement at 12 Weeks³




A robust data set demonstrates that PTNS with Urgent PC is effective with consistent results in 3 randomised controlled trials (RCTs), 3 durability studies, 2 meta-analyses and over 50 peer-reviewed articles.

Statistically superior to sham in reducing frequency, incontinence episodes, nighttime voids and urgency³


Superior subjective response to leading drugs with statistically significant reductions in OAB symptoms^{4,5}

At 3 years follow-up, all quality of life (QoL) parameters remained markedly improved with about 1 treatment a month (all p<0.0001)⁶

URGENT® PC OBJECTIVE SUCCESS
Results from RCTs and Meta-Analyses



URGENT® PC SUSTAINED EFFECTIVENESS⁶



THE PROVEN PTNS DEVICE



URGENT® PC NEUROMODULATION SYSTEM

- Option for most patients experiencing associated symptoms of OAB such as urinary urgency, urinary frequency, and urge incontinence
- Up to 80% patient response in men and women¹⁻⁹
- More than a million treatments since 2003
- Easy to integrate into clinical practice

CATALOG NUMBER	PRODUCT DESCRIPTION	PROCEDURE REQUIREMENTS
UPC 200	Reusable Urgent® PC Stimulator 1 Hand-held Stimulator, 1 9-Volt Battery, 1 Screwdriver, 1 Instructions for Use	1 unit
UPC 250-12	Urgent PC Lead Sets 12 Lead Sets/box, 1 9-Volt Battery, 1 Instructions for Use	1 lead set

1. Peters, K., Carrico, D. (2013). Clinical insights into percutaneous tibial nerve stimulation (PTNS) versus sham therapy for the treatment of overactive bladder syndrome (OAB): secondary analysis of the SUMIT Trial. Poster presentation, SUFU winter meeting, Las Vegas, NV.
2. Hashim, H., Beusterien, K., Bridges, J.G., Amos, K. & Cardozo, L. (2015). Patient preferences for treating refractory overactive bladder in the UK. *Int Urol Nephrol*. Sept. 7 [Epub ahead of print].
3. Peters, K.M., Carrico, D.J., Perez-Marrero, R.A., Khan, A.U., Wooldridge, L.S., Davis, G.L., et al. (2010). Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUMIT Trial. *J Urol*, 183, 1438-43.
4. Peters, K.M., Leong, F.C., Shobeiri, S.A., MacDiarmid, S.A., Rovner, E.S., Wooldridge, L.S., et al. (2009). A randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the Overactive Bladder Innovative Therapy trial. *J Urol*, 182, 1055-61.
5. Vecchioli-Scaldazza, C., Morosetti, C., Beouz, A., Giannubilo, W., Ferrara, V. (2013). Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. *Gynecol Obstet Invest*, 75(4), 230-4.
6. Peters, K.M., Carrico, D.J., Wooldridge, L.S., Miller, C.J. & MacDiarmid, S.A. (2013). Percutaneous tibial nerve stimulation (PTNS) for the long-term treatment of overactive bladder: three-year results of the STEP Study. *J Urol*, 189(6), 2194-2201.
7. Finazzi-Agrò, E., Petta, F., Sciobica, F., Pasqualetti, P., Musco, S., & Bove, P. (2010). Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. *J Urol*, 184, 2001-06.
8. MacDiarmid, S.A., & Staskin, D.R. (2009). Percutaneous tibial nerve stimulation (PTNS): a literature-based assessment. *Curr Blad Dysf Rept*, 4, 29-33.
9. Burton, C., Sajja, A., & Latthe, P.M. (2012). Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systemic review and meta-analysis. *NeuroUrol Urodyn*, 31(8), 1206-16.

CONTRAINDICATIONS: Treatment with Urgent PC is contraindicated for patients with pacemakers or implantable defibrillators, patients prone to excessive bleeding, patients with nerve damage that could impact either percutaneous tibial nerve or pelvic floor function, or patients who are pregnant or planning to become pregnant during the duration of the treatment.

PRECAUTION: Exercise caution for patients with heart problems related to pacing. Most patients do not experience side-effects. If side-effects occur, they are typically temporary and include mild pain and skin inflammation at or near the stimulation site. For complete instructions for use, storage, warnings, indications, contraindications, precautions, adverse reactions and disclaimer of warranties, please refer to the insert accompanying each Urgent PC product. Models are for illustrative purpose only. Urgent and BOTOX are registered trademarks. Urgent PC is manufactured by Uroplasty LLC. ©2018 LABORIE. All rights reserved.



Distributed in Australia by
Endotherapeutics ABN 89 088 045 103
 Level 1, 51 Rawson St, Epping NSW 2121
 T: 1300 00 3636 F: +61 (2) 9869 7723
 E: info@endotherapeutics.com.au
www.endotherapeutics.com.au



EUROPE/INTERNATIONAL:
 Tel.: +31 53 4803700
 Email: info@laborie.com

HEADQUARTERS:
 Tel.: +1 905 612 1170
 Email: marketing@laborie.com



www.laborie.com